Alnylam Pharmaceuticals, Inc. Q2 2026 Earnings Recap

Alnylam’s shares plunged 28.3% post-earnings as the company lowered its 2026 revenue guidance, disappointing investors with signs of demand normalization and a cautious outlook amid early second-line demand tapering.

Key Takeaways

• 2026 revenue guidance was reduced to reflect normalized demand following an initial surge driven by pent-up second-line patient starts.
• AMVUTTRA revenues surpassed $1 billion in Q2, marking an annualized run rate above $4 billion, but growth is shifting heavily towards first-line new patient starts (~80% of category growth).
• The company cited competitive headwinds, including the failure of a rival’s cardiovascular outcomes trial, but maintained confidence in its Phase III TRITON-CM study with potential study adaptations under consideration.
• Geographic expansion efforts continue, notably a new collaboration targeting the China and Macau markets, contingent on regulatory approval.
• Investment in AI-driven discovery and disease identification partnerships underscores a longer-term innovation strategy despite short-term growth challenges.